• Mashup Score: 0

    February 21, 2022 – Nuwellis, Inc. has announced the company will evaluate the clinical outcomes and economic value of its Aquadex therapy in comparison to intravenous diuretics for the treatment of fluid overload in patients with worsening heart failure through its randomized controlled trial, Ultrafiltration Versus IV Diuretics in Worsening Heart Failure, the REVERSE-HF Study. REVERSE-HF is a…

    Tweet Tweets with this article
    • @DAICeditor @Nuwellis_Inc The company will evaluate the clinical outcomes of its #Aquadex therapy in comparison to #intravenous #diuretics for the treatment of fluid overload in patients with worsening #heartfailure through the #REVERSE_HF Study: https://t.co/95SGqsN7Oc

  • Mashup Score: 0

    Expansion of extracellular fluid volume is central to the pathophysiology of heart failure. Increased extracellular fluid leads to elevated intracardiac filling pressures, resulting in a constellation of signs and symptoms of heart failure referred to as congestion. Loop diuretics are one of the cornerstones of treatments for heart failure, but in contrast to other therapies, robust clinical…

    Tweet Tweets with this article
    • Link to full State of The Art Review 2/2 #Diuretics #HeartFailure https://t.co/c0mPghoOTw